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Background: Narcolepsy is a severe sleep-wake cycle disorder resulting in most cases from a 
lack of orexin, the energy balance-regulating hormone. Narcoleptic patients have been reported 
to suffer from an excess morbidity of Type 2 diabetes, even after correction for their often 
elevated body mass index.
Methods: To explore whether narcolepsy is specifically associated with a propensity to develop 
insulin resistance, we measured fasting glucose, insulin, and intact proinsulin levels in 43 narco-
leptic patients and 47 controls matched for body mass index and age. The proinsulin-to-insulin 
ratio was calculated. Insulin resistance was determined using the homeostatic model assess-
ment method.
Results: Narcoleptic patients did not show elevated insulin resistance parameters.
Conclusion: In contrast with earlier reports, we found no evidence that narcolepsy specifically 
elevates the risk of insulin resistance (and consequently of type 2 diabetes) independently of 
body mass index.
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Introduction
Narcolepsy is a rare disease that affects approximately 0.05% of the population in 
Western countries. It is typically characterized by excessive daytime sleepiness, 
cataplexy, sleep onset rapid eye movement sleep periods, and the presence of the 
human leukocyte antigen (HLA) DQB1*0602 allele.1 The association between the 
DQA1*0102/DQB1*0602 alleles and narcolepsy is among the strongest HLA associa-
tions in medicine, and suggests an autoimmune pathogenesis of the disorder.2 There 
is evidence that the hypocretin/orexin neurotransmission system is involved in the 
pathophysiology of narcolepsy. Orexin, a neurotransmitter which is produced by a 
restricted set of cells located in the hypothalamus, is not only involved in the regula-
tion of sleep but also plays a role in energy expenditure and body weight regulation. 
It promotes feeding behavior. Food intake leads to decreased activity of orexinergic 
neurons and lower orexin levels, and fasting leads to an increased orexin level.3–8   
The role of orexin suggests that hypocretin deficiency in narcoleptic patients should 
lead to reduced food intake and loss of body weight.5,6 Surprisingly, it has been 
found that narcoleptic patients have higher body mass indices than community-based 
samples.9–11 Moreover, Honda et al reported a prevalence of type 2 diabetes mellitus 
in six of 48 narcoleptic patients (12.5%). They concluded that the tendency towards Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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diabetes might be independent of body mass index (BMI) 
because there were no differences in the prevalence between 
the obese and nonobese narcoleptic patients. Ever since then, 
it is commonly understood that narcoleptic patients have an 
increased risk of developing type 2 diabetes.11
Recently a research group from Italy conducted a very 
detailed study on metabolic alterations in narcoleptic patients, 
including measurement of BMI, waist circumference, blood 
pressure, daily calorie intake (three-day diary), and bio-
chemical and hormonal parameters (cholesterol, insulin, and 
leptin, among others).12 They found that nine of 14 patients 
displayed the metabolic syndrome compared with 14 age- 
and gender-matched patients with idiopathic hypersomnia, of 
whom none were affected. Although the study was carefully 
performed, there were several limitations, including a small 
sample size and especially the fact that both groups were not 
BMI-matched (patients with narcolepsy 28 ± 4.4, patients 
with idiopathic hypersomnia 24.2 ± 2.8, P = 0.012), because 
BMI is one of the greatest influencing factors of the metabolic 
syndrome besides age. Even individuals in the upper normal 
weight and slightly overweight BMI range are at increased 
risk of having the metabolic syndrome.13–16
In order to increase the sensitivity and power of our 
own study we focused on insulin resistance, one of the 
pathophysiological components of type 2 diabetes and 
metabolic   syndrome.17 Many studies have shown that 
insulin resistance will progress to overt diabetes or meta-
bolic syndrome within only a few years.18–20 In insulin 
resistance, the pancreas compensates for the increased 
insulin to maintain normal blood glucose levels. However, 
the intracellular processing capacities may soon become 
exhausted and incomplete processing of the insulin leads to 
increased release of intact or partly processed proinsulin.21 
Once the beta cell secretion fails to maintain glucose 
control, impaired glucose tolerance and diabetes mellitus 
are the consequences.22 The hyperinsulinemic-euglycemic 
clamp technique and the intravenous glucose tolerance 
test are the gold standard methods for measuring insulin 
sensitivity.23,24 Both are very time- and resource-consuming 
and not suitable for routine clinical use. Therefore, we used 
a composite of surrogate parameters to assess insulin resis-
tance in our patients by measuring insulin and glucose for 
calculation of the homeostasis assessment model of insulin 
resistance (HOMA-IR) score25 in narcoleptic patients and 
controls matched for age, gender, and BMI. We also deter-
mined intact proinsulin to calculate the proinsulin-to-insulin 
ratio and to determine the prevalence of insulin resistance 
as described by Pfützner et al.21
Methods
Patients
The study design was approved by the ethics committee 
of the Medical Association of Rhineland-Palatinate that is 
responsible for all clinical studies performed at the University 
of Mainz. The study was conducted in accordance with all 
relevant ethical and legal regulations. All participants gave 
their written informed consent prior to study entry. A total 
of 43 patients (22 males and 21 females) with a diagnosis 
of narcolepsy according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) and 
the International Classification of Sleep Disorders (ICSD) 
criteria were enrolled into this cross-sectional investigation.26 
Patients were all unrelated and were either referred from 
the Department of Psychiatry, University Hospital Mainz, 
or recruited with the help of the Deutsche Narkolepsie-
Gesellschaft, a nationwide German patient organization. 
  Narcolepsy symptoms, severity and frequency of symptoms, 
and total duration of various aspects of the symptomatol-
ogy were assessed by unstructured and structured clinical 
interviews, including the Stanford Center for Narcolepsy 
Sleep Inventory (www.med.stanford.edu/school/Psychiatry/
narcolepsy/sleepinventory.pdf). In accordance with the 
ICSD II for the diagnosis of narcolepsy, patients who had 
not undergone polysomnographic examination were only 
admitted to the study when unambiguous cataplexies, addi-
tional rapid eye movement-associated symptoms, and severe 
daytime sleepiness with recurrent daytime naps or lapses into 
sleep for at least three months were reported. To exclude 
symptomatic narcolepsy, the medical history was assessed 
and a neurologic examination was performed.
As a control group, 47 healthy unrelated volunteers 
(22 males and 25 females) matched for age and gender 
were recruited. All controls had undergone an oral glucose 
tolerance test to exclude diabetes mellitus. Further exclusion 
criteria were pregnancy, multiple allergies, drug abuse, or any 
other psychiatric disorders limiting the capacity to consent. 
All participants were of Caucasian origin.
Measurements
Glucose levels were determined using a standard reference 
laboratory method (glucose oxidase method) according to 
the manufacturer’s instructions (Super GL, RLT, Möhnesee, 
  Germany). Insulin and intact proinsulin were determined as 
previously described27 by means of specific immunoassays 
(MLT insulin [intra-assay and interassay coefficients of varia-
tion 3.8% and 2.3%, respectively, reference range ,30 µU/mL] 
and LINCO Intact Proinsulin [intra-assay and interassay Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  coefficients of variation 5.2% and 8.6%,   respectively, reference 
range ,10 pmol/L], LINCO Research Inc, St Charles, MO).
The proinsulin-to-insulin ratio was calculated by dividing 
the concentration of proinsulin (pmol/L) by insulin (converted 
from µU/mL into pmol/L). Insulin resistance was diagnosed 
based on prevalence of elevated fasting intact proinsulin21,28 or 
elevated fasting HOMA-IR score   calculation.25 The estimate of 
insulin resistance by HOMA-IR score was calculated as fasting 
serum insulin (µU/mL) × fasting plasma glucose (mg/dL)/405. 
As described by Hedblad et al patients with HOMA scores 
exceeding the 75th percentile of a nondiabetic patient popula-
tion (ie, 2.0) were considered to have insulin resistance.29
statistical analysis
Statistical analysis was performed using descriptive statis-
tics and appropriate parametric and nonparametric tests. 
The Kolmogorov–Smirnov test was used to ensure that the 
studied variables did not significantly differ from a normal 
  distribution. The Mann–Whitney U test was used to compare 
rank sums. For the comparison of proportions, the Chi-square 
test was used. Descriptive results of continuous variables were 
expressed as the median and interquartile range for the non-
Gaussian variables. All tests were two-sided.   Linear regres-
sion was used to analyze the impact of BMI and age on the 
parameters of insulin resistance. Results with P values ,0.05 
were considered to be statistically   significant. All calcula-
tions were conducted with SPSS software (version 15.0 for 
Windows, SPSS Inc, Chicago, IL).
Results
A general characterization of patients and controls is given 
in Table 1.
Fasting glucose
Median fasting plasma glucose was significantly lower 
in the narcoleptic patients as compared with the healthy 
controls (narcoleptic patients 85.0 [76.0–95.0] mg/dL, 
controls 96.5 [87.5–102.8] mg/dL, P , 0.001). The differ-
ences were also conserved in the gender subgroups (male 
narcoleptic patients 86.0 [81.3–103.5] mg/dL; controls 
101.0 [93.8–108.3] mg/dL, P = 0.031; female narcoleptic 
patients 78.0 [72.5–88.0] mg/dL; controls 93.3 [85.3–93.3] 
mg/dL, P = 0.001). One control and one narcoleptic patient 
had fasting glucose values above .126 mg/dL (P = 0.987). 
Fasting glucose correlated with BMI in narcoleptic patients 
(r = 0.384, P = 0.011) and controls (r = 0.349, P = 0.020) and 
with age in the narcoleptic group (r = 0.339, P = 0.026), but 
not in the control group (r = 0.247, P = 0.106).
insulin
Median insulin levels were 7.58 (5.6–11.6) µU/mL in 
  narcoleptic patients and 10.14 (6.9–13.7) µU/mL in controls 
(P = 0.185). Accordingly, median insulin levels in narco-
leptic females (6.50 [5.5–10.0] µU/mL) were not different 
from female controls (8.06 [4.5–10.3] µU/mL, P = 0.680) 
and median insulin levels in male narcoleptic patients were 
similar to those in male controls (narcoleptic patients 9.40 
[6.1–17.0] µU/mL; controls 11.20 [10.1–15.9] µU/mL, 
P = 0.205). Five narcoleptic patients and four controls had 
values above 17 µU/mL (P = 0.698). Insulin levels did 
correlate with BMI in both diagnostic groups (narcoleptic 
patients: r = 0.413, P = 0.006; controls r = 0.522, P , 0.001) 
and did not correlate with age (narcoleptic patients: r = 0.077, 
P = 0.622; controls r = 0.172, P = 0.266).
intact proinsulin
Median intact proinsulin values were slightly higher in 
  controls than in narcoleptic patients (narcoleptic patients 
2.46 [1.3–6.3] pmol/L versus controls 3.82 [2.4–7.1] pmol/L, 
P = 0.046). Intact proinsulin medians were 2.83 (1.9–9.4) 
pmol/L in narcoleptic men and 1.6 (1.1–3.4) pmol/L in narco-
leptic women. The corresponding values for the male controls 
were 5.32 (3.8–9.9) pmol/L (P = 0.060) and 2.4 (1.6–2.4) 
for the female controls (P = 0.172). Five narcoleptic patients 
and three controls showed intact proinsulin values above 
11 pmol/L (P = 0.382), ie, the reference value for stage III 
Table 1 characterization of patients and controls
Characteristics Narcoleptic  
patients
Controls P value
n 43 47
Males 22 (51.2%) 22 (46.8%)
Females 21 (48.9%) 25 (53.2%)
Age (years) 49.2 ± 16.6 50.6 ± 16.3 0.678
(Males) 54.5 ± 15.3 55.1 ± 15.3 0.891
(Females) 43.7 ± 16.5 46.7 ± 16.5 0.535
BMi (kg/m²) 30.2 ± 6.1 31.0 ± 5.2 0.505
(Males) 31.4 ± 5.2 32.4 ± 4.0 0.481
(Females) 28.8 ± 6.8 29.7 ± 5.8 0.655
hLA Dr15 positive 38 (88.4%) n.a.
(Males) 20 (90.9%)
(Females) 18 (85.7%)
hLA Dr15 negative 5 (11.6%)
(Males) 2 (9.1%)
(Females) 3 (14.3%)
Duration of  
narcolepsy (years)
29.8 ± 17.2
Age of onset (years) 16.0 (12.0–23.0)
Ess score 18.14 ± 3.68
Abbreviations: BMi, body mass index; hLA, human leukocyte antigen; Ess, Epworth   
sleepiness score; n.a., not asked.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table  2  glucose  levels,  insulin,  intact  proinsulin,  proinsulin-
to-insulin  ratio,  and  homeostasis  assessment  model  of  insulin 
resistance of narcoleptic patients and control subjects, values are 
given as median (quartiles). Additionally, both groups were split 
for gender
Narcoleptics Controls P value
Fasting glucose 
(mg/dL)
85.0 (76.0–95.0) 96.5 (87.5–102.8) ,0.001
Males 86.0 (81.3–103.5) 101.0 (93.8–108.3) 0.031
Females 78.0 (72.5–88.0) 93.3 (85.3–93.3) 0.001
insulin (µU/mL) 7.58 (5.6–11.6) 10.14 (6.9–13.7) 0.185
Males 9.40 (6.1–17.0) 11.20 (10.1–15.9) 0.205
Females 6.50 (5.5–10.0) 8.06 (4.5–10.3) 0.680
intact proinsulin 
(pmol/L)
2.46 (1.3–6.3) 3.82 (2.4–7.1) 0.046
Males 2.83 (1.9–9.4) 5.23 (3.8–9.9) 0.060
Females 1.63 (1.1–3.4) 2.38 (1.6–2.4) 0.172
Proinsulin-to- 
insulin ratio (%)
4.31 (3.0–7.0) 5.35 (4.4–8.1) 0.033
Males 4.99 (3.1–8.8) 6.16 (4.8–10.6) 0.250
Females 3.52 (2.4–6.0) 5.07 (3.6–6.1) 0.055
hOMA index 1.51 (1.1–3.1) 2.68 (1.6–3.5) 0.048
Males 2.01 (1.3–3.6) 2.96 (2.6–3.9) 0.096
Females 1.3 (1.0–2.0) 1.96 (1.0–2.0) 0.264
Abbreviation: hOMA, homeostatic model assessment.
beta cell dysfunction and insulin resistance.16 In both groups, 
there was a significant correlation between intact proinsulin 
and BMI (narcoleptic patients: r = 0.464, P = 0.002; controls 
r = 0.485, P = 0.001). Correlations of proinsulin with age 
were r = 0.243 (narcoleptic patients, P = 0.116) and r = 0.308 
(controls, P = 0.035). The proinsulin-to-insulin ratio was 
marginally lower in narcoleptic patients than in the controls 
(narcoleptic patients 4.31 versus controls 5.35, P = 0.033).
hOMA-ir
Median HOMA values were 1.51 (1.1–3.1) for   narcoleptic 
patients and 2.68 (1.6–3.5) for controls (P = 0.048). 
HOMA . 2.5 were found in 12 patients (27.9%) and 23 
controls (52.3%, P = 0.020). Two patients and two controls 
had HOMA values .5 (P = 0.981). HOMA correlated 
with BMI in both diagnostic groups (narcoleptic patients: 
r = 0.489, P = 0.001; controls r = 0.474, P = 0.001) but not 
with age (narcoleptic patients: r = 0.195, P = 0.209; controls 
r = 0.236, P = 0.123).
insulin resistance
Insulin resistance, defined as fasting glucose levels 
.126 mg/dL, insulin levels above 17 µU/mL, intact proinsulin 
values above 11 pmol/L, and HOMA values .5, was preva-
lent in one narcoleptic patient (2.3%) and not in any controls 
(P = 0.478). Insulin resistance, as defined by a HOMA-IR 
score .2.0 and increased fasting intact proinsulin levels,21 
was present in four narcoleptic patients (9.3%) and three of the 
healthy control subjects (6.4%, P = 0.450). A summary of the 
results is also given in Table 2. Linear regression analysis with 
fasting glucose, insulin, intact proinsulin, and HOMA-IR as 
dependent variables and BMI and age as independent variables 
showed no impact of BMI on intact proinsulin (P = 0.557) but 
did show an impact on fasting glucose (P = 0.015), insulin 
(P , 0.001), and HOMA-IR (P , 0.001). No impact of age 
was found for insulin (P = 0.400), intact proinsulin (P = 0.869), 
and HOMA-IR (P = 0.908) but did show an impact for fasting 
glucose (P = 0.016). None of the markers were correlated with 
disease duration (data not shown).
Discussion
In our study, narcoleptic patients did not show higher fasting 
blood glucose levels than age- and BMI-matched controls. 
Also, insulin and intact proinsulin levels were not elevated in 
the narcoleptic group, nor was the proinsulin-to-insulin ratio, 
HOMA-IR-levels, or prevalence of insulin resistance. This 
result is in contrast with the clinical belief that narcolepsy per 
se and independently from BMI is associated with an increased 
(pre) diabetic metabolic state. Our conclusion is supported by 
the fact that all controls were examined by an oral glucose toler-
ance test prior to inclusion in the study and in this way manifest 
diabetes was excluded from the control group. Therefore, the 
only potential bias was in favor of an overestimation of potential 
markers of prediabetes in the narcoleptic patients.
One limitation of the study is that because of the low 
prevalence of narcolepsy, it was not possible to recruit a 
strictly representative population sample. Instead, patients 
were recruited with the support of a patient organization. It 
has been estimated that a large fraction of narcoleptic patients 
in the general population are undiagnosed.30 This problem 
is unavoidable when studying rare disorders and is true for 
most, if not all, published narcolepsy studies. However, we 
took care not to introduce additional bias by embedding our 
study in a study of overweight and metabolic parameters 
with no explicit reference to type 2 diabetes. 
A second limitation is the choice of the observation 
parameters. In particular, no oral glucose tolerance test, 
intravenous glucose tolerance test, or hyperinsulinemic-
euglycemic clamp test were performed in the narcoleptic 
patients. Although being a very simple, cheap, and con-
venient parameter (and recommended by the American 
Diabetes Association),31 fasting glucose alone is poorly 
predictive of insulin resistance and a very crude parameter Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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for   assessing beta cell function.32–34 Fasting glucose also has 
a poor   sensitivity for diabetes diagnosis (40%–60%) and may 
delay the diagnosis of dysglycemia.35 Waugh et al found 
that the majority of patients with impaired glucose tolerance 
would be missed by assessing only fasting plasma glucose 
levels.36 Nevertheless, elevated fasting glucose levels are 
predictive for manifest diabetes.22,31
Although fasting insulin is considered to be a relatively 
good indicator of insulin resistance among nondiabetic 
persons,37 other studies have revealed that the relationship 
between insulin resistance measured by an euglycemic clamp 
and fasting serum insulin level is weak. Insulin levels are 
less suited to yield a diagnosis in the single patient than to 
study metabolic tendencies in groups.38,39 Intact proinsulin 
has been shown to be a highly specific indirect marker for 
insulin resistance. Elevation of intact proinsulin values 
above the reference range (.11 pmol/L) shows a very high 
specificity and a moderate sensitivity as a marker for insulin 
resistance.21 Plasma intact proinsulin concentrations are usu-
ally highest in patients with type 2 diabetes, lower in those 
with normal glucose tolerance, and moderately elevated in 
patients with impaired glucose tolerance. The results reported 
by Reaven show that ambient plasma proinsulin concentra-
tions increase as glucose tolerance declines.13
In addition, impaired glucose tolerance in type 2 diabetes 
is often characterized by an increased ratio of proinsulin to 
insulin. The results reported by Mykkanen et al suggest that 
an increased intact proinsulin-to-insulin ratio is a marker 
of defective insulin secretion.40,41 While this group con-
sidered the proinsulin-to-insulin ratio to be a good marker 
for impaired beta cell function, Vezzosi et al found that the 
proinsulin-to-insulin ratio did not result in better diagnostic 
accuracy than proinsulin levels alone. Because there are no 
commonly accepted reference ranges set for the ratio, we 
compared our results with other research papers and found 
values of 1%–16% described to be physiological.41–44
The HOMA method is derived from a mathematical 
assessment of the interaction between beta cell function and 
insulin resistance in an idealized model, which is then used 
to compute steady-state insulin and glucose concentrations. 
The output of the model is calibrated to give normal beta cell 
function of 100% and a normal insulin resistance of 1. Once 
this interrelationship is calculated, one can estimate beta cell 
function and insulin resistance for any pair of fasting plasma 
glucose and insulin concentrations. The HOMA model has 
proved to be a reliable clinical and epidemiological instrument 
to describe the pathophysiology of diabetes, except in the stage 
of severe beta cell dysfunction leading to proinsulin secretion.25 
Taken together, the combined   measurement of fasting glucose, 
insulin, and intact proinsulin is a practical and robust way to 
not only diagnose manifest diabetics but also to characterize 
prediabetic metabolic states.28
In summary, we found no evidence that narcolepsy 
elevates the risk for prediabetic states of insulin resistance 
independently of BMI. The fact that the narcoleptic patients 
had even lower insulin resistance parameters than the controls 
might give the wrong impression that narcoleptic patients 
have a smaller risk of developing type 2 diabetes. This effect 
still needs to be elucidated. Clinically, type 2 diabetes still 
remains a challenge in narcoleptic patients because of the 
association of narcolepsy with an elevated BMI.
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